IMIsabelle Munoz

Isabelle Munoz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabelle Munoz has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Leveraging endogenous 3’ cis-regulatory elements to refine tumor-restricted armoring of CAR T cells for improved safety and potency

    by Paul Beavis, Kah Min Yap, Amanda Chen, Yu-Kuan Huang, Jesse Armitage, Phoebe Dunbar, Katherine Audsley, Dat Nguyen, Junming Tong, Thang Hoang, et al.

    Armoring chimeric antigen receptor (CAR) T cells with cytokines is a promising strategy to overcome immunosuppression in solid tumors, but is frequently limited by toxicities arising from systemic cytokine expression. Previously, we developed a CRISPR/Cas9-based engineering strategy that leverages the regulatory mechanisms of endogenous genes to enable tumor-restricted transgene expression in CAR T cells. Herein, we describe a next-generation strategy that preserves endogenous target gene expression and retains regulatory architecture in the 3’ untranslated region (UTR) during transgene integration. At the RGS16 locus, this strategy markedly tightened transgene activation, resulting in highly tumor-localized delivery of IL-12 and IL-2 across both xenogeneic and syngeneic models. Mechanistically, this enhanced precision was mediated by retention of the 3’UTR. This regulatory feature was conserved across additional tumor-specific loci, supporting 3′UTR-mediated regulation as a broadly applicable mechanism for refining transgene control. Together, these findings establish a versatile engineering platform for the precise and safe armoring of CAR T cells in solid tumors.

  • Rôle de la kinésine-1 dans le sécrétions régulées des celulles immunitaires

    by Isabelle Munoz

    La plupart des cellules du système immunitaire sont des cellules sécrétrices capables de libérer des molécules immuno-modulatrices en réponse à des stimuli variés. Cette sécrétion régulée qui permet l’orchestration de la réponse immunitaire et inflammatoire est assurée grâce aux organites apparentés aux lysosomes (LRO) qui vont contenir les molécules nécessaires à la fonctionnalité des cellules immunes. On retrouve par exemple les granules lytiques des lymphocytes T cytotoxiques qui permettent à ces cellules d’effectuer leurs fonctions lytiques ou encore les granules de sécrétion des mastocytes qui contiennent les médiateurs de l’inflammation. Le transport et l’exocytose des LRO impliquent une machinerie commune et conservée. C’est notamment le cas de la petite GTPase Rab27 qui joue un rôle central dans le transport et la sécrétion de ces LRO. De précédentes études réalisées au sein de notre laboratoire ont pu mettre en évidence l’implication du complexe moléculaire Rab27a/Slp3/kinésine-1 dans le transport terminal des granules lytiques des lymphocytes T cytotoxiques chez l’homme. De plus, un modèle murin dont la chaîne lourde de la kinésine-1 est spécifiquement invalidée dans les cellules immunitaires a pu être généré. L’objectif de ma thèse a été dans un premier temps de caractériser le phénotype de ce modèle murin déficient pour la kinésine-1 puis d’analyser plus précisément l’impact de l’absence de la kinésine-1 sur la fonctionnalité des lymphocytes T cytotoxiques et mastocytes murins. Dans un premier temps nous avons pu montrer que les souris déficientes pour la kinésine-1 ont un phénotype comparable à celui des souris contrôles à l’état basal. Nous avons ensuite montré que l’absence de la kinésine-1 au sein des lymphocytes T cytotoxiques murins n’induit pas de défauts d’activation et de sécrétion des granules lytiques in vitro. Cependant les comportements des granules lytiques à la synapse immunologique semblent anormaux. Néanmoins après un test d’infection au LCMV, qui ne révèle aucunes différences entre les souris contrôles et déficientes en kinésine-1, nous en venons à la conclusion que des mécanismes compensateurs pourraient compenser l’absence de la kinésine-1 dans les lymphocytes T cytotoxiques chez la souris. Pour finir des études fonctionnelles réalisées au niveau des mastocytes murins nous ont permis de mettre en évidence l’implication de la kinésine-1 dans le mécanisme de transport des granules de sécrétion. En effet, l’absence de kinésine-1 conduit à des défauts de dégranulation des mastocytes in vitro mais aussi in vivo (souris moins sensibles aux chocs anaphylactiques). En revanche l’absence de kinésine-1 n’affecte pas les capacités d’activation et de sécrétion des cytokines des mastocytes. Enfin, nous avons pu caractériser le complexe moléculaire Rab27b/Slp3/kinésine-1 impliqué dans le transport des granules mastocytaires et avons pu constater que la formation de ce complexe était dépendante de la voie d’activation liée à la PI3K (Phospatidylinositol 3-kinase). Ce travail permet d’apporter de nouveaux éléments quant aux mécanismes gouvernant la sécrétion des granules mastocytaires et ouvre ainsi de nouvelles perspectives thérapeutiques pour le traitement des hypersensibilités de type 1 (dépendantes des IgE).

  • Open Access

    High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion

    by Maria N. de Menezes, Amanda X. Y. Chen, Nihali Kulkarni, Shienny Sampurno, Nicole Y. L. Saw, Kah Min Yap, Iván Pérez-Núñez, Sara Roth, Christian Deo T. Deguit, Brandon Haugen, et al.

    CD8+ T cell exhaustion is a regulatory state triggered by chronic antigen stimulation in both cancer and persistent infection. The less differentiated stem-like sub-populations of exhausted T cells have been heavily studied given their importance to the efficacy of current immunotherapies. While the transcription factor TCF1 is both necessary and sufficient for formation and maintenance of these stem-like populations, it remains unclear whether TCF1 can actively de-differentiate more terminally exhausted subsets back into a stem-like state. To address this question, here we utilize and optimize a high efficiency CRISPR knock-in methodology, compatible with mouse in vivo exhaustion models, to engineer T cells that either constitutively over-express TCF1, or conditionally over-express TCF1 following differentiation of the cells into a CX3CR1+ intermediate-exhausted state. Strikingly, we find that only constitutive, and not conditional, TCF1 over-expression can increase the size of the stem-like T cell pool. Thus, while TCF1 can slow stem-like T cell differentiation, it is insufficient to revert more differentiated cells back into a stem-like state.


  • Open Access

    Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes

    by Junyun Lai, Cheok Weng Chan, Jesse D. Armitage, Katherine M. Audsley, Yu-Kuan Huang, Emily B. Derrick, Laura S. Carstensen, Christina M. Scheffler, Matt E. Jones, Kevin Sek, et al.

    Immune checkpoint blockade (ICB) evokes antitumor immunity through the reinvigoration of T cell responses. T cell differentiation status controls response, with less differentiated cells having an enhanced capacity to proliferate after ICB. Given that conventional type 1 dendritic cells (cDC1) maintain precursor exhausted T cells (TPEX), we hypothesized that expansion of cDC1s with Flt3L could enhance responses to ICB. Here we show that treatment with Fms-related tyrosine kinase 3 ligand (Flt3L) expands CD62L+SLAMF6+CD8+ T cells in the tumor through a mechanism that requires XCR1+ dendritic cells to traffic to the tumor-draining lymph node. The combination of Flt3L and anti-CTLA-4 enhanced therapeutic responses. Combination therapy is associated with the emergence of a CD8+ T cell subset characterized by the expression of Il21r and oligoclonal expansion of CD8+ T cells within tumors through a mechanism that is dependent on lymph node egress.


  • Open Access

    Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

    by Kevin Sek, Amanda X. Y. Chen, Thomas Cole, Jesse D. Armitage, Junming Tong, Kah Min Yap, Isabelle Munoz, Phoebe A. Dunbar, Shiyi Wu, Marit J. van Elsas, et al.

    The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor. To overcome this, Chimeric Antigen Receptor T cells are engineered to express A1 receptor, a receptor that signals inversely to A2A receptor. Using murine and human Chimeric Antigen Receptor T cells, constitutive A1 receptor overexpression significantly enhances Chimeric Antigen Receptor T cell effector function albeit at the expense of Chimeric Antigen Receptor T cell persistence. Through a CRISPR/Cas9 homology directed repair “knock-in” approach we demonstrate that Chimeric Antigen Receptor T cells engineered to express A1 receptor in a tumor-localized manner, enhances anti-tumor therapeutic efficacy. This is dependent on the transcription factor IRF8 and is transcriptionally unique when compared to A2A receptor deletion. This data provides a novel approach for enhancing Chimeric Antigen Receptor T cell efficacy in solid tumors and provides proof of principle for site-directed expression of factors that promote effector T cell differentiation.


  • Top Cited Papers
    Open Access

    Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery

    by Amanda X. Y. Chen, Kah Min Yap, Joelle S. Kim, Kevin Sek, Yu-Kuan Huang, Phoebe A. Dunbar, Volker Wiebking, Jesse D. Armitage, Isabelle Munoz, Kirsten L. Todd, et al.

    The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity1,2,3. To overcome these barriers, ‘armoured’ CAR T cells, which secrete proinflammatory cytokines, have been developed4. However, their clinical application has been limited because of toxicity related to peripheral expression of the armouring transgene5. Here, we have developed a CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumour-localized manner. By screening endogenous genes with tumour-restricted expression, we have identified the NR4A2 and RGS16 promoters as promising candidates to support the delivery of cytokines such as IL-12 and IL-2 directly to the tumour site, leading to enhanced antitumour efficacy and long-term survival of mice in both syngeneic and xenogeneic models. This effect was concomitant with improved CAR T cell polyfunctionality, activation of endogenous antitumour immunity and a favourable safety profile, and was applicable in CAR T cells from patients.


  • Open Access

    CRISPR engineering of armored CAR T cells enables tumor restricted payload delivery with enhanced efficacy and safety

    by Amanda Chen, Kah Min Yap, Joelle Kim, Kevin Sek, Yu-Kuan Huang, Phoebe Dunbar, Volker Wiebking, Jesse Armitage, Isabelle Munoz, Kirsten Todd, et al.

    The efficacy of chimeric antig en receptor (CAR) T cell therapy in solid tumors is limited by immunosuppression and antigen heterogeneity. To overcome these barriers, “armored” CAR T cells, which secrete proinflammatory cytokines, have been developed. However, their clinical application has been limited due to toxicities related to peripheral expression of the armoring transgene. Here, we developed a novel CRISPR knock-in strategy that uses endogenous gene regulatory mechanisms to drive transgene expression in a tumor-localized manner. By screening endogenous genes with tumor-restricted expression, the NR4A2 and RGS16 promoters were identified to support the delivery of cytokines such as IL-12 and IL-2 directly to the tumor site, leading to enhanced anti-tumor efficacy and long-term survival of mice in both syngeneic and xenogeneic models. This was concomitant with improved CAR T cell polyfunctionality, activation of endogenous anti-tumor immunity, a favorable safety profile, and was applicable using CAR T cells from patients.

  • Top Cited Papers
    Open Access

    FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

    by Jack D. Chan, Christina M. Scheffler, Isabelle Munoz, Kevin Sek, Joel N. Lee, Yu-Kuan Huang, Kah Min Yap, Nicole Y. L. Saw, Jasmine Li, Amanda X. Y. Chen, et al.

    Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma1–4, but the efficacy of CAR T cell therapy in solid tumours has been limited5. This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. Analysis of anti-CD19 CAR T cells used clinically has shown that positive treatment outcomes are associated with a more ‘stem-like’ phenotype and increased mitochondrial mass6–8. We therefore sought to identify transcription factors that could enhance CAR T cell fitness and efficacy against solid tumours. Here we show that overexpression of FOXO1 promotes a stem-like phenotype in CAR T cells derived from either healthy human donors or patients, which correlates with improved mitochondrial fitness, persistence and therapeutic efficacy in vivo. This work thus reveals an engineering approach to genetically enforce a favourable metabolic phenotype that has high translational potential to improve the efficacy of CAR T cells against solid tumours.


  • Open Access

    Tumor-site directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

    by Phillip Darcy, Kevin Sek, Amanda Chen, Thomas Cole, Jesse Armitage, Junming Tong, Kah Min Yap, Isabelle Munoz, Phoebe Dunbar, Lauren Giuffrida, et al.

    The efficacy of Chimeric Antigen Receptor (CAR) T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment (TME) including adenosine, which suppresses CAR T cells through activation of the A2A receptor (A2AR). To overcome this, CAR T cells were engineered to express A1R, a receptor that signals inversely to A2AR. Using murine and human CAR T cells, constitutive A1R overexpression was demonstrated to significantly enhance CAR T cell effector function albeit at the expense of CAR T cell persistence. Through a novel CRISPR/Cas9 “knock-in” approach we demonstrated that CAR T cells engineered to express A1R in a tumor-localized manner, led to enhanced anti-tumor efficacy dependent on the transcription factor IRF8. This data provides a novel approach for enhancing CAR T cell efficacy in solid tumors and provides proof of principle for site-directed expression of factors that promote effector T cell differentiation.

  • Open Access

    Overexpression of FOXO1 enhances CAR T cell polyfunctionality, metabolic fitness and efficacy against solid tumors

    by Paul Beavis, Phillip Darcy, Junyun Lai, Jack Chan, Kevin Sek, Christina Scheffler, Isabelle Munoz, Yu-Kuan Huang, Kah Min Yap, Joel Lee, et al.

    The efficacy of chimeric antigen receptor (CAR) T cell therapy is limited in solid tumors by several factors including the immunosuppressive tumor microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. To overcome this, we sought to identify transcription factors that could enhance CAR T cell fitness. We identified that the overexpression of Foxo1 could enhance the therapeutic efficacy of murine CAR T cells in the setting of syngeneic immunocompetent models and was dependent on the sustained production of proinflammatory cytokines. FOXO1 overexpression in human CAR T cells enforced broad transcriptional and epigenetic changes that led to a more “stem-like” phenotype and similarly improved therapeutic efficacy. Enhanced efficacy was associated with improved mitochondrial fitness and persistence in vivo. FOXO1 overexpression also led to a more stem like phenotype in patient derived CAR T cells and is therefore a promising strategy for the treatment of solid cancers.